Cargando…

COVID-19: Abnormal liver function tests

BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnorm...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Qingxian, Huang, Deliang, Yu, Hong, Zhu, Zhibin, Xia, Zhang, Su, Yinan, Li, Zhiwei, Zhou, Guangde, Gou, Jizhou, Qu, Jiuxin, Sun, Yan, Liu, Yingxia, He, Qing, Chen, Jun, Liu, Lei, Xu, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Association for the Study of the Liver. Published by Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194951/
https://www.ncbi.nlm.nih.gov/pubmed/32298767
http://dx.doi.org/10.1016/j.jhep.2020.04.006
_version_ 1783528438158589952
author Cai, Qingxian
Huang, Deliang
Yu, Hong
Zhu, Zhibin
Xia, Zhang
Su, Yinan
Li, Zhiwei
Zhou, Guangde
Gou, Jizhou
Qu, Jiuxin
Sun, Yan
Liu, Yingxia
He, Qing
Chen, Jun
Liu, Lei
Xu, Lin
author_facet Cai, Qingxian
Huang, Deliang
Yu, Hong
Zhu, Zhibin
Xia, Zhang
Su, Yinan
Li, Zhiwei
Zhou, Guangde
Gou, Jizhou
Qu, Jiuxin
Sun, Yan
Liu, Yingxia
He, Qing
Chen, Jun
Liu, Lei
Xu, Lin
author_sort Cai, Qingxian
collection PubMed
description BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver test results. METHODS: Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information on clinical features of patients with abnormal liver tests were collected for analysis. RESULTS: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients having alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels elevated to more than 3× the upper limit of normal, respectively. Patients with abnormal liver tests of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios [ORs] 2.73; 95% CI 1.19–6.3, and 4.44, 95% CI 1.93–10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both p <0.01). CONCLUSION: Patients with abnormal liver tests were at higher risk of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, which should be monitored and evaluated frequently. LAY SUMMARY: Data on liver tests in patients with COVID-19 are scarce. We observed a high prevalence of liver test abnormalities and liver injury in 417 patients with COVID-19 admitted to our referral center, and the prevalence increased substantially during hospitalization. The presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia. The detrimental effects on liver injury were related to certain medications used during hospitalization, which warrants frequent monitoring and evaluation for these patients.
format Online
Article
Text
id pubmed-7194951
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Association for the Study of the Liver. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71949512020-05-02 COVID-19: Abnormal liver function tests Cai, Qingxian Huang, Deliang Yu, Hong Zhu, Zhibin Xia, Zhang Su, Yinan Li, Zhiwei Zhou, Guangde Gou, Jizhou Qu, Jiuxin Sun, Yan Liu, Yingxia He, Qing Chen, Jun Liu, Lei Xu, Lin J Hepatol Research Article BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver test results. METHODS: Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information on clinical features of patients with abnormal liver tests were collected for analysis. RESULTS: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients having alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels elevated to more than 3× the upper limit of normal, respectively. Patients with abnormal liver tests of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios [ORs] 2.73; 95% CI 1.19–6.3, and 4.44, 95% CI 1.93–10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both p <0.01). CONCLUSION: Patients with abnormal liver tests were at higher risk of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, which should be monitored and evaluated frequently. LAY SUMMARY: Data on liver tests in patients with COVID-19 are scarce. We observed a high prevalence of liver test abnormalities and liver injury in 417 patients with COVID-19 admitted to our referral center, and the prevalence increased substantially during hospitalization. The presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia. The detrimental effects on liver injury were related to certain medications used during hospitalization, which warrants frequent monitoring and evaluation for these patients. European Association for the Study of the Liver. Published by Elsevier B.V. 2020-09 2020-04-13 /pmc/articles/PMC7194951/ /pubmed/32298767 http://dx.doi.org/10.1016/j.jhep.2020.04.006 Text en © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Research Article
Cai, Qingxian
Huang, Deliang
Yu, Hong
Zhu, Zhibin
Xia, Zhang
Su, Yinan
Li, Zhiwei
Zhou, Guangde
Gou, Jizhou
Qu, Jiuxin
Sun, Yan
Liu, Yingxia
He, Qing
Chen, Jun
Liu, Lei
Xu, Lin
COVID-19: Abnormal liver function tests
title COVID-19: Abnormal liver function tests
title_full COVID-19: Abnormal liver function tests
title_fullStr COVID-19: Abnormal liver function tests
title_full_unstemmed COVID-19: Abnormal liver function tests
title_short COVID-19: Abnormal liver function tests
title_sort covid-19: abnormal liver function tests
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194951/
https://www.ncbi.nlm.nih.gov/pubmed/32298767
http://dx.doi.org/10.1016/j.jhep.2020.04.006
work_keys_str_mv AT caiqingxian covid19abnormalliverfunctiontests
AT huangdeliang covid19abnormalliverfunctiontests
AT yuhong covid19abnormalliverfunctiontests
AT zhuzhibin covid19abnormalliverfunctiontests
AT xiazhang covid19abnormalliverfunctiontests
AT suyinan covid19abnormalliverfunctiontests
AT lizhiwei covid19abnormalliverfunctiontests
AT zhouguangde covid19abnormalliverfunctiontests
AT goujizhou covid19abnormalliverfunctiontests
AT qujiuxin covid19abnormalliverfunctiontests
AT sunyan covid19abnormalliverfunctiontests
AT liuyingxia covid19abnormalliverfunctiontests
AT heqing covid19abnormalliverfunctiontests
AT chenjun covid19abnormalliverfunctiontests
AT liulei covid19abnormalliverfunctiontests
AT xulin covid19abnormalliverfunctiontests